ALGS: Aligos Therapeutics Inc. Company Short-Term Debt
Aligos Therapeutics (ALGS) is currently in the clinical testing stage, where research expenses generate a constant cash outflow. The company's short-term borrowings confirm this burden, while 0.00 reflects the baseline level of the metric. While trial failure risks and competition pose threats, high R&D costs and patents protect the business from new entrants.
Aligos Therapeutics Inc. - analytical breakdowns and key metrics (ALGS)
This metric assesses the ratio of current borrowings to working capital, determining the balance between the issuer's solvency and investment potential. For Aligos Therapeutics (ALGS), which is developing liver therapies through strategic alliances, credit obligations under one year reflect the ability to fund clinical trials without default risk, confirming the high reliability of the company's asset structure.